Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis

Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis

Aims: Medical and non-medical switching strategies have been adopted in Europe in the last few years. We aimed to investigate persistence on treatment with a SB5 Adalimumab (SB5) biosimilar after switching from Adalimumab (ADA) originator among patients with inflammatory rheumatic musculoskeletal di...

Full description

Bibliographic Details
Main Authors: Cosimo Bruni, Stefano Gentileschi, Giovanni Pacini, Marco Bardelli, Lorenzo Tofani, Francesca Bartoli, Caterina Baldi, Laura Cometi, Ginevra Fiori, Francesca Nacci, Luca Cantarini, Serena Guiducci, Alberto Moggi-Pignone, Bruno Frediani, Marco Matucci-Cerinic
Format: Article
Language:English
Published: SAGE Publishing 2021-07-01
Series:Therapeutic Advances in Musculoskeletal Disease
Online Access:https://doi.org/10.1177/1759720X211033679

Internet

https://doi.org/10.1177/1759720X211033679

Similar Items